Clinical trials: Genetic Hemochromatosis
Hereditary Hemochromatosis C282Y Homozygous
HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis
HFE(High iron FE)-related hereditary hemochromatosis has a highly variable penetrance. No phenotypic or genetic markers can predict the disease.
- Trial name
- HEPFER (NCT01784939)
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Rennes University Hospital
Hemochromatosis
Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy
In this project we plan to evaluate the effectiveness of erythrocytapheresis against phlebotomy, both regarding the impact on the reduction in iron overload as well as reduction in patient "burden".
- Trial name
- NCT00202436
- Testing
- Phlebotomy, Erythrocytapheresis
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Sanquin Research & Blood Bank Divisions
Hereditary Hemochromatosis
PTG-300 in Subjects With Hereditary Hemochromatosis
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
- Trial name
- NCT04202965
- Testing
- PTG-300
- Where
- 11 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Protagonist Therapeutics, Inc.
Sickle Cell Disease
Liver Fibrosis in Sickle Cell Disease
Patients with sickle cell disease many have a number of systemic complications, including liver problems. Some of these liver problems lead to liver fibrosis/cirrhosis, secondary to chronic blood transfusions.
- Trial name
- NCT02007746
- Testing
- Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Miami
Hereditary Hemochromatosis
Cardiac Function in Patients With Hereditary Hemochromatosis
This study will examine the effect of iron buildup in the hearts of patients with hereditary hemochromatosis (HH), a genetic disease that causes the body to accumulate excess amounts of iron.
- Trial name
- NCT00068159
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Transfusional Iron Overload, Iron Overload
Treatment of Iron Overload Requiring Chelation Therapy
The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron…
- Conditions
- Transfusional Iron Overload, Iron Overload, Iron Chelation, Beta-thalassemia
- Trial name
- NCT01927913
- Testing
- SPD602, Deferasirox
- Sponsor
- Shire
Hereditary Haemochromatosis
Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?
Haemochromatosis is a preventable genetic iron overload disorder. Untreated, it can shorten life due mainly to liver cirrhosis and cancer. It can be prevented by blood donation to maintain normal iron levels.
- Trial name
- Mi-iron (NCT01631708)
- Testing
- Erythrocytapheresis, Plasmapheresis
- Where
- 3 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Hereditary Hemochromatosis
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
The purpose of this study was to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with Hereditary Hemochromatosis (HH) at risk of…
- Trial name
- NCT03203850
- Testing
- Deferasirox FCT, Phlebotomy
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Hemochromatosis, Iron Overload
MRI QSM Imaging for Iron Overload
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron…
- Trial name
- NCT04631718
- Testing
- Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Wisconsin, Madison
Diabetes Mellitus, Heart Disease
Deferoxamine for the Treatment of Hemochromatosis
When patients receive repeated blood transfusions the level of iron in the patient s blood can rise. When iron is processed in the body a protein known as hemosiderin can begin collecting in the organs.
- Conditions
- Diabetes Mellitus, Heart Disease, Hemochromatosis, Thalassemia
- Trial name
- NCT00001203
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
The safety, tolerability, effects on liver iron concentration and pharmacokinetics of ICL670 is studied in sickle cell disease patients with transfusional hemosiderosis.
- Trial name
- NCT01090323
- Testing
- ICL670
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Iron Metabolism Disorders, Iron Overload
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
Polyphenolic compounds are very strong Inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron.
- Conditions
- Iron Metabolism Disorders, Iron Overload, Polyphenols
- Trial name
- NCT03990181
- Testing
- meal matrix & NPPS, meal matrix & CS, no-matrix & NPPS
- Where
- 2 sites in Portugal, Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Thalassemia Major, Hemosiderosis
Efficacy Study in Removing Excess Iron From the Heart
The purpose of this study is to determine whether deferiprone has superior efficacy in removing excess iron from the heart when compared with deferoxamine.
- Trial name
- NCT00105495
- Testing
- Ferriprox (deferiprone), Desferal (deferoxamine)
- Where
- 4 sites in Greece, Italy
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Beta-thalassemia Major, Sickle Cell Disease
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload Primary Outcome Measures: The…
- Conditions
- Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis
- Trial name
- NCT01511848
- Testing
- DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Hemochromatosis
Haemochromatosis and Periodontitis
Periodontitis is a chronic inflammatory disease that affects tissues surrounding the teeth. It is strongly associated with the major pathogenic "red complex", including Porphyromonas gingivalis, Tannerella forsythia and Treponema…
- Trial name
- HEMOPARO (NCT04006249)
- Testing
- dental probes
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Rennes University Hospital
Hereditary Hemochromatosis
A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
This study is a Phase 2 multicenter, randomized, placebo controlled, single-blind study. The primary objective of the study is to compare the effect of weekly dosing of LJPC-401 (synthetic human hepcidin) versus placebo on…
- Trial name
- NCT03395704
- Testing
- LJPC-401
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- La Jolla Pharmaceutical Company
Anemia, Sickle Cell, Transfusion Hemosiderosis
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Hypothesis: The investigators suspect that significant degrees of iron overload in subjects with SCD result in decreased red cell survival, abnormal endothelial function and markedly dysregulated autonomic function.
- Trial name
- NCT00981370
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Los Angeles
Hereditary Haemochromatosis
Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis
Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality of life and the delivered quality of care in the hospital.
- Trial name
- NCT01991925
- Testing
- Interviews, questionaires, RAND-modified delphi method round
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Blood Disease, Hemochromatosis
Hemochromatosis and Iron Overload Screening Study (HEIRS)
To determine the prevalence, genetic and environmental determinants, and potential clinical, personal, and societal impact of iron overload and hereditary hemochromatosis, in a multi-center, multiethnic, primary care-based sample…
- Conditions
- Blood Disease, Hemochromatosis, Iron Overload
- Trial name
- NCT00005541
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hemochromatosis, Cerebrovascular Accident
Stroke With Transfusions Changing to Hydroxyurea
The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with…
- Conditions
- Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
- Trial name
- NCT00122980
- Testing
- Red Cell Transfusions, Iron Chelation, Hydroxyurea
- Where
- 28 sites in United States
- Volunteers
- 134 people
- Sponsor
- St. Jude Children's Research Hospital